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Abstract
Background: Several beneficial effects have been demonstrated for secretogranin II (SgII) in non-cardiac tissue. As cardiac
production of chromogranin A and B, two related proteins, is increased in heart failure (HF), we hypothesized that SgII could
play a role in cardiovascular pathophysiology.
Methodology/Principal Findings: SgII production was characterized in a post-myocardial infarction heart failure (HF) mouse
model, functional properties explored in experimental models, and circulating levels measured in mice and patients with
stable HF of moderate severity. SgII mRNA levels were 10.5 fold upregulated in the left ventricle (LV) of animals with
myocardial infarction and HF (p,0.001 vs. sham-operated animals). SgII protein levels were also increased in the LV, but not
in other organs investigated. SgII was produced in several cell types in the myocardium and cardiomyocyte synthesis of SgII
was potently induced by transforming growth factor-b and norepinephrine stimulation in vitro. Processing of SgII to shorter
peptides was enhanced in the failing myocardium due to increased levels of the proteases PC1/3 and PC2 and circulating
SgII levels were increased in mice with HF. Examining a pathophysiological role of SgII in the initial phase of post-infarction
HF, the SgII fragment secretoneurin reduced myocardial ischemia-reperfusion injury and cardiomyocyte apoptosis by 30%
and rapidly increased cardiomyocyte Erk1/2 and Stat3 phosphorylation. SgII levels were also higher in patients with stable,
chronic HF compared to age- and gender-matched control subjects: median 0.16 (Q1–3 0.14–0.18) vs. 0.12 (0.10–0.14) nmol/
L, p,0.001.
Conclusions: We demonstrate increased myocardial SgII production and processing in the LV in animals with myocardial
infarction and HF, which could be beneficial as the SgII fragment secretoneurin protects from ischemia-reperfusion injury
and cardiomyocyte apoptosis. Circulating SgII levels are also increased in patients with chronic, stable HF and may represent
a new cardiac biomarker.
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Introduction
Heart failure (HF) is associated with changes in systemic and
pulmonary hemodynamics, complex neurohumoral activation, as
well as local molecular alterations in the myocardium [1]. Given
that coronary artery disease is a leading cause of HF [1], a better
understanding of the pathophysiology of myocardial ischemia and
HF development is needed. Regulation of hormonal factors in the
failing myocardium can directly affect function and survival of
cardiac cells [1], and result in increased circulating levels of
proteins secreted from the myocardium [2]. Thus, by identifying
proteins that are regulated in the failing myocardium, we may
enhance our understanding of the pathophysiology of HF and
discover new diagnostic and prognostic HF biomarkers.
The protein secretogranin II (SgII) is a 587 amino acid long
protein from the chromogranin-secretogranin (granin) protein
family [3]. Two other members of the granin protein family,
chromogranin (Cg) A and B have been found increased in HF [4–
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e374016], and may represent novel cardiac biomarkers [4–9]. In addition,
chromogranins may affect myocardial function in HF [10,11]. For
SgII, functional aspects have mainly been attributed to the short
33 amino acid peptide secretoneurin (SgII154–186) and a number of
interesting pathophysiological effects have been reported in other
organs than the heart [3]. SgII production is increased by hypoxia
in skeletal muscle [12], and secretoneurin protects against
apoptosis and ischemic injury in the brain and skeletal muscle
[13,14]. The proteases PC1/3 and PC2 have been identified as the
principal proteases for processing of SgII to shorter fragments
[15,16]. As other granin proteins appear to be upregulated during
HF development, we hypothesized that SgII production is
increased in the myocardium and circulation in HF, and that
SgII could play a role in the pathophysiology of HF following
myocardial ischemia.
Results
Left Ventricular SgII Gene Expression is Upregulated
During HF Development
To study SgII production in the left ventricle (LV) in HF, we
first compared SgII mRNA levels in non-infarcted LV tissue of HF
animals to levels in sham animals. HF animals exhibited increased
lung weights and increased LV and right ventricular mass,
reflecting pulmonary congestion and compensatory myocardial
hypertrophy (Table 1). By echocardiography, the HF animals also
had marked LV dilatation and increased left atrial size compared
to sham animals (Table 1). Furthermore, mass spectrometry
peptide mass fingerprinting of a very strong band in Commassie
stained gels from pulmonary tissue of HF mice identified albumin,
which is a testament to the pronounced congestion and leakage of
proteins into the lungs of our HF mice (Supporting Information
S1).
LV SgII mRNA levels were markedly upregulated in HF
animals compared to sham animals (10.5 fold increase,
p,0.001, Figure 1A). This was a greater relative increase than
observed for B-type natriuretic peptide (BNP), CgA, or CgB
mRNA levels (Table 1). SgII mRNA levels correlated signifi-
cantly with CgA mRNA levels in HF (r=0.68, p=0.04,
Figure 1B), but not with CgB or BNP mRNA levels (Supporting
Information Table S1).
SgII Production is Increased in the LV in HF
In parallel with observed alterations in SgII mRNA expression,
protein levels of SgII were significantly increased in both the non-
infarcted (35% increase, p=0.007) and the infarcted region of the
LV (85% increase, p,0.001) in HF animals as measured by
radioimmunoassay (RIA) (Figure 2A). As previously reported for
chromogranins [6,17], SgII immunoreactivity was evident in
cardiomyocytes, however, we also found SgII immunoreactivity in
endothelial cells, fibroblasts, and other infiltrative cells of the
border zone and the infarcted area (Figure 2B). The production of
SgII in several cell types of the myocardium was validated by
demonstrating similar SgII mRNA levels in fractions of cardio-
myocytes, endothelial cells, and non-cardiomyocyte, non-endo-
thelial cells (Figure 2C).
The complex processing of SgII (Figure 3A) [3,18] was
examined by immunoblotting, and we identified increased
processing of SgII to shorter SgII fragments in the myocardium
of HF animals compared to sham animals (Figure 3B). Finally,
levels of the SgII protease PC1/3 were potently increased in both
the left and right ventricle of HF animals, while the active form of
the SgII protease PC2 (68 kDa) [19] was only increased in
infarcted LV tissue of HF animals (110% increase, p=0.02)
(Figure 3C).
SgII Production was not Increased in Other Tissues
Investigated
To further study SgII production in HF, we measured SgII
protein levels in non-cardiac tissue by RIA. As illustrated in
Figure 4, SgII levels were not altered in the right ventricle,
liver, spleen, kidney, stomach, colon, and skeletal muscle during
HF development, while SgII levels were decreased by 19%
(p=0.03) in pulmonary tissue of HF animals. The immunore-
activity of short SgII bands was stronger in pulmonary tissue of
HF animals (Figure 3B) although PC1/3 or PC2 activity were
not significantly increased (Figure 3C). We did not see changes
in SgII processing in the other organs examined (immunoblot of
tissue from the stomach is included as an example in Figure 3).
Circulating SgII Levels are Increased in HF Mice
Circulating SgII levels were increased in HF animals (n=14)
compared to sham animals (n=8): 0.4460.04 vs.
0.3560.01 nmol/L, p=0.049. In the HF group, animals with
SgII levels above the mean had more pronounced LV dilatation in
systole compared to the other HF mice: 5.760.1 vs. 5.460.1 mm,
p=0.04.
Table 1. Descriptive statistics of animals.
Sham
(n=21)
HF
(n=27) p
Animal weight, day 0 (g) 24.460.4 24.460.4 0.95
Lung weight/tibial length (g/
mm)
0.07960.001 0.15660.007 ,0.001
LV mass/tibial length (g/mm) 0.04560.001 0.05860.001 ,0.001
RV mass/tibial length (g/mm) 0.01160.001 0.01360.001 0.01
LV CgA mRNA levels 1.060.4 4.861.4 0.02
LV CgB mRNA levels 1.060.1 5.260.7 ,0.001
LV BNP mRNA levels 1.060.1 5.860.7 ,0.001
IVSd (mm) 0.860.1 0.360.0 ,0.001
IVSs (mm) 1.260.1 0.460.0 ,0.001
LVDd (mm) 3.760.2 6.060.1 ,0.001
LVDs (mm) 2.460.2 5.560.1 ,0.001
LVFS (%) 18668 61 0.11
PWd (mm) 0.860.1 0.760.0 0.37
PWs (mm) 1.160.1 1.060.1 0.32
LAD (mm) 1.660.1 2.760.1 ,0.001
LV indicates left ventricle; RV, right ventricle; CgA, chromogranin A; CgB,
chromogranin B; BNP, B-type natriuretic peptide; IVSd, intraventricular septum
thickness in diastole; IVSs, intraventricular septum thickness in systole; LVDd, LV
diameter in diastole; LVDs, LV diameter in systole; LVFS, LV fractional
shortening; PWd, posterior wall thickness in diastole; PWs, posterior wall
thickness in systole; and LAD, left atrial diameter.
mRNA levels were investigated in a subset of animals (n=9 HF, n=8 sham) and
are presented as fold change6SEM. Echocardiographic data are reported as
mean6SEM and are obtained from a representative subset of animals (13 HF
animals, 6 sham animals).
doi:10.1371/journal.pone.0037401.t001
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Increase SgII Gene Expression in Cardiomyocytes
As multiple endocrine and paracrine factors are known to
influence cardiomyocyte protein synthesis [1], we examined
possible factors that could influence SgII production in cardio-
myocytes. Stimulating neonatal rat cardiomyocytes in vitro for 24 h
with transforming growth factor-b (TGF-b) and norepinephrine
(NE) increased SgII mRNA levels by 85% (p,0.001) and 35%
(p=0.02), respectively, while exposure to angiotensin II (AngII),
endothelin-1 (ET-1), and tumor necrosis factor-a (TNF-a) did not
affect SgII production (Figure 5). Forskolin (FSK), which has been
shown to induce SgII mRNA expression in other cell types [20],
was used as a positive control and increased SgII mRNA levels in
isolated cardiomyocytes by 35% (p=0.001).
The SgII Fragment Secretoneurin Reduces Ischemia/
Reperfusion Injury in the Isolated Perfused Rat Heart
As SgII production was increased in the infarcted LV of post-
infarction HF mice, and infarct size is a major determinant for HF
development [21], we assessed whether the SgII fragment
secretoneurin could protect against damage after myocardial
ischemia. In a global ischemia/reperfusion (I/R) model of the
isolated perfused rat heart, the addition of secretoneurin to the
buffer reduced infarct size by 30% (p=0.047) after 30 min of
ischemia and 2 h of reperfusion (Figure 6A). The beneficial effects
of secretoneurin on I/R damage were also evidenced by lower LV
end-diastolic pressure in the hearts perfused with secretoneurin
(Figure 6B).
Secretoneurin Stimulation Increases Stat3 and Erk1/2
Phosphorylation and Reduces Hydrogen Peroxide-
induced Apoptosis in Isolated Cardiomyocytes
Reduced apoptosis in cardiomyocytes at risk could be a
mechanism by which secretoneurin protects the myocardium
after I/R injury. We therefore investigated whether secretoneurin
plays a role in the protection of cardiomyocytes exposed to
hydrogen peroxide (H2O2). Exposure of H2O2 to cardiomyocytes
markedly induced apoptosis, as indicated by measurements of
DNA fragmentation (Figure 6C). We observed that the proportion
of apoptotic cells after H2O2 exposure was 30% lower (p=0.005)
in cells co-stimulated with secretoneurin compared to cells in
standard medium. Finally, we examined signaling pathways that
could account for the effects of secretoneurin on I/R injury and
cardiomyocyte apoptosis. Phospho AktSer473, Erk1/2Thr202/Tyr204,
and Stat3Ser727/Tyr705 levels were measured in cardiomyocytes
after short-term secretoneurin exposure. Secretoneurin stimulation
significantly increased Erk1/2Thr202/Tyr204 phosphorylation (four
and two fold increase after 10 and 30 min, respectively, p=0.04)
(Figure 6D). Stat3Ser727 phosphorylation was increased after
10 min of secretoneurin exposure (100% increase, p=0.04), while
phospho Stat3Tyr705 and AktSer473 levels were unaltered.
Circulating Levels of SgII are Increased in Patients with
Chronic, Stable HF
To validate the results of the experimental model, and to
demonstrate increased SgII levels also in chronic, stable HF,
circulating SgII levels in 58 patients with chronic HF were
compared to levels in 20 age- and gender-matched healthy control
subjects (Table 2). In this cohort of stable HF patients treated
according to updated guidelines, SgII levels were higher than
levels in the control group: median 0.16 (Q1–3 0.14–0.18) vs. 0.12
(0.10–0.14) nmol/L, p,0.001 (Figure 7). Plasma levels of SgII
correlated with BNP in HF patients (r=0.26, p=0.05), but not in
control subjects (r=0.19, p=0.43). SgII levels did not correlate
with CgA or CgB levels in control subjects or HF patients
(Supporting Information Table S2). As evaluated by receiver
operating analysis, circulating levels of SgII were more closely
regulated in HF than both CgA (AUC=0.84 for SgII vs.
AUC=0.57 for CgA, p=0.001) and CgB levels (AUC=0.68 for
CgB, p=0.03 vs. SgII). Use of a proton pump inhibitor (PPI), a
medication known to increase circulating CgA levels [6], did not
Figure 1. Left ventricular SgII gene expression in heart failure. A, SgII mRNA levels in non-infarcted left ventricular tissue during HF
development. SgII mRNA levels were 10.5 fold increased (p,0.001) in non-infarcted LV tissue in HF animals (n=9) compared to sham-operated
animals (n=8). Gene expression was measured by RT-qPCR and is presented as fold change 6 SEM. B, LV SgII mRNA levels were closely correlated
with CgA mRNA levels in both HF (r=0.68, p=0.04) and sham animals (r=0.81, p=0.02). **p,0.001.
doi:10.1371/journal.pone.0037401.g001
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37401Figure 2. SgII is produced by cardiomyocytes and increased in the left ventricle during HF development. A, SgII protein levels as
measured by RIA were increased in both the non-infarcted and infarcted region of the LV in HF animals compared to levels in the myocardium of
sham-operated animals (n=9 for both groups). B, Representative photomicrographs of myocardial tissue sections of a HF mouse demonstrating SgII
immunoreactivity (brown staining) in cardiomyocytes of the non-infarcted LV (upper left image). Images of the area bordering the infarcted zone
(border zone) are presented in the upper right image (magnification: 6100) and the lower left image (magnification: 6400) and demonstrate SgII
immunoreactivity also in non-cardiomyocyte cardiac cells, including fibroblasts. In the upper right image, the infarct area is seen on the left side with
granulation tissue in between non-infarcted tissue in the center. Bottom right picture demonstrates very weak staining after use of non-immune
rabbit serum as control (ctr). Magnification:6100 except lower left image (6400). C, SgII mRNA levels were measured in fractions of cardiomyocytes
(n=5), endothelial cells (n=2), and non-cardiomyocytes, non-endothelial cells (n=5) extracted from LV tissue. Gene expression was measured by RT-
qPCR and is presented as fold change 6 SEM vs. levels in the cardiomyocyte fraction. **p,0.001, *p,0.01.
doi:10.1371/journal.pone.0037401.g002
Figure 3. SgII processing is increased in the myocardium of HF mice. A, Figure of SgII processing as reported in non-cardiac tissue (modified
from ref. 18). B, SgII processing in myocardial tissue, pulmonary tissue, and tissue from the stomach. Bands at 81, 66, 55, and 32-30 kDa were
measured and are presented as fold change (SEM) vs. sham animals (n=6 for each group). C, Levels of the proteases PC1/3 and PC2 in HF and sham
animals.
doi:10.1371/journal.pone.0037401.g003
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similar to SgII levels in the other HF patients: 0.16 (Q1–3 0.13–
0.19) vs. 0.16 (0.14–0.18) nmol/L, respectively, p=0.68).
Discussion
In the present study we demonstrate for the first time that the
expression of SgII, a member of the granin protein family, is
increased in the LV during HF development. Moreover, SgII
processing to shorter fragments is increased in the myocardium in
post-infarction HF, which could be beneficial as the SgII fragment
secretoneurin protects against myocardial I/R injury and cardio-
myocyte apoptosis. SgII production was not increased in other
tissues investigated, and therefore the heart could be a significant
contributor to the elevated circulating SgII levels in patients with
HF.
Myocardial Production of SgII in HF
HF is associated with increased myocardial production of
several protein families [1,2]. Like other granin proteins, SgII is a
pro-hormone with multiple dibasic cleavage sites [3]. Although the
processing of SgII is known to be more complex than for most
other pro-hormones [3,22], SgII has in several tissues been
demonstrated to be almost fully processed to the short 33 amino
acid peptide secretoneurin [23]. In the circulation, the majority of
SgII immunoractivity is also reportedly found in the form of
secretoneurin [23]. Pertinent to this, data from non-cardiac tissue
have indicated that cells with an enhanced secretory rate exhibit
increased processing of SgII to shorter fragments [18]. Accord-
ingly, our novel data demonstrating increased levels and process-
ing of SgII to shorter fragments in the myocardium during post-
myocardial infarction HF point to the heart as a significant
contributor to the increased circulating levels of SgII in HF. This is
supported by the lack of increase in SgII production in non-
cardiac tissue in HF as measured by RIA. Still, as immunoreac-
tivity of short SgII bands in the lungs of HF animals were
increased, we cannot preclude a contribution also by pulmonary
tissue to circulating SgII levels. However, the full-length pro-form
of SgII was not evident in pulmonary tissue and no increment in
PC1/3 or PC2 activity was demonstrated. Thus, another
possibility is leakage of SgII immunoreactivity from the circulation
to the lungs due to severe pulmonary congestion. Mass spectrom-
etry peptide mass fingerprinting of a very strong band in
Commassie stained gels from pulmonary tissue of HF mice
identified albumin, which is a testament to the pronounced
congestion and leakage of proteins into the lungs of our HF mice.
Figure 4. SgII production outside of the left ventricle in heart failure. SgII levels were decreased in pulmonary tissue during HF
development, while levels were unchanged in the other tissues examined. SgII levels in the (A) right ventricle, (B) pulmonary tissue, (C) liver, (D)
spleen, (E) kidney, (F) stomach, (G) colon, and (H) skeletal muscle were measured by RIA and are presented as fold change 6 SEM (n=6 for both
groups, except pulmonary tissue: HF: n=14, sham: n=13). # p,0.05.
doi:10.1371/journal.pone.0037401.g004
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37401The mechanism by which SgII processing is increased seems to
be enhanced PC1/3 (previously denoted PC1 or PC3) and PC2
activity in the LV, which are the principal proteases of SgII
[15,16]. The complex processing of SgII in the myocardium with
several shorter fragments corresponds to immunoblots of SgII
processing in non-cardiac tissue [15,16,18,22,23]. One report has
previously demonstrated increased PC1/3 mRNA levels close to
the infarct area in rats with myocardial infarction and HF [24],
but to our knowledge the increase in both PC1/3 and PC2 in the
LV of animals with HF has previously not been reported.
Increased PC1/3 and PC2 activity has been hypothesized as a
conceptual model for enhanced SgII processing in non-cardiac
cells [18].
We identified cardiomyocytes as contributors to the SgII
production in the myocardium. This is in line with previous data
for chromogranins [6,17], and with a report published during
progression of our work that demonstrates the presence of SgII in
the healthy rodent myocardium [25]. We have also previously
demonstrated that NE, TGF-b, and AngII regulate CgB
production in cardiomyocytes [6]. Similar to this, we now report
that TGF-b and NE both induce SgII mRNA expression in
cardiomyocytes in vitro, while AngII failed to increase SgII mRNA
levels. Distinct regulation of different granins has been reported in
other cell types and may be explained by variations in the
promoter region, including the serum response element (SRE),
which is only found in the SgII promoter [20]. Effect of growth
factors on SRE promoter sites could explain the potency of TGF-b
as a stimulus for SgII production in cardiomyocytes [20], but the
precise mechanism regulating cardiomyocyte SgII production
needs to be established in future studies. This also relates to a
possible role of hypoxia-inducible factor-1a (HIF-1a)a sa
regulator of SgII production after myocardial ischemia. Indeed,
HIF-1a has previously been found to increase SgII production in
skeletal muscle subjected to hypoxia [12], and we found SgII
production increased in the LV of animals with myocardial
infarction and HF. However, in contrast to data for chromo-
granins [6,17], we also find SgII to be produced by non-
cardiomyocyte cardiac cells, including endothelial cells and cell
fractions with a high proportion of cardiac fibroblasts. The
mechanism controlling SgII production in non-cardiomyocytes
needs to be established in subsequent studies, along with the
relative contribution by the different cell types to myocardial SgII
production in HF.
Functional Aspects of the SgII Fragment Secretoneurin in
the Myocardium
Proteins produced by the heart during the development of HF
may exert their actions via endocrine, paracrine or autocrine
mechanisms [1]. Findings in the current study suggest that SgII
and the fragment secretoneurin could exert important effects in
the myocardium by reducing I/R injury and cardiomyocyte
apoptosis. These effects of secretoneurin, together with the
observation that LV SgII levels and processing are increased in
animals with myocardial infarction and HF, are compatible with
known functional properties of secretoneurin. Secretoneurin has
previously been found to attract leukocytes, especially monocytes
[26], and may be of importance for the early post-infarction
inflammatory response in the myocardium. Secretoneurin also
attracts endothelial cells, both mature endothelial cells for
angiogenesis [27] and bone marrow-derived progenitor endothe-
lial cells for vasculogenesis [28], suggesting that secretoneurin
could play a role in revascularization of infarcted myocardial
tissue. Hence, the mechanism by which secretoneurin induces
revascularization are likely both recruitment of bone-marrow
derived cells to produce new vessels and local sprouting of vessels
[13,14], potentially mediated by a nitric oxide-dependent mech-
anism analogous to what has been reported in the hindlimb
ischemia model [14].
In this study, we have shown for the first time that
secretoneurin attenuates cardiomyocyte apoptosis and reduces
infarct size in the subacute phase after myocardial infarction. A
putative mechanism for this effect of secretoneurin against I/R
injury is via reduction of cardiomyocyte apoptosis in the border
zone, possibly mediated by Erk1/2 and Stat3 activation [29,30].
Stat3 may represent a direct link between secretoneurin and
reduced opening of the mitochondrial permeability transition
pore [31], whereas the mechanism by which Erk1/2 reduces
apoptosis seems to be mediated through additional downstream
molecules [32]. Other studies have also shown secretoneurin to
protect endothelial cells from apoptosis through Erk1/2
signaling [27,28], and to attenuate neuronal cell death after
ischemia by induction of the Jak/Stat pathway [13], providing
support for secretoneurin as a protective factor in the subacute
phase of tissue ischemia. Hence, based on our data of increased
SgII production and processing in the infarcted area, SgII and
secretoneurin production seem to represent an endogenous
protective mechanism during post-infarction HF development.
With infarct size being considered a major determinant of post-
infarction HF development [21], we believe these results are
relevant also for myocardial function in the more chronic stages
of HF. However, we have not assessed the long-term effects of
increased SgII levels for organ function in HF and this should
be explored in future studies. Before the long-term effects of
secretoneurin have been established, the net effect by increased
SgII levels in HF cannot be estimated, although we provide
evidence that LV SgII production seems to be protective in the
subacute phase of post-infarction HF development.
The exact mechanism by which secretoneurin mediates the
protection during I/R injury and cardiomyocyte apoptosis is yet to
be established. A previous report suggested that monocytes have
functionally active binding sites for secretoneurin [33], but after
Figure 5. Regulation of cardiomyocyte SgII expression by
important hormonal and paracrine factors in HF. SgII mRNA
levels were measured by RT-qPCR after stimulating neonatal rat
cardiomyocytes for 24 h with either PBS (Ctr, n=9), forskolin (FSK
n=5), norepinephrine (NE, n=5), angiotensin II (AngII, n=4), endothe-
lin-1 (ET-1, n=5), transforming growth factor-b (TGF-b, n=6), or tumor
necrosis factor-a (TNF-a, n=6). SgII mRNA levels are presented as fold
change 6 SEM vs. PBS-stimulated cells. **p,0.001, *p,0.01, # p,0.05.
doi:10.1371/journal.pone.0037401.g005
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37401more than 25 years of research, the putative receptor for
secretoneurin has not been characterized. The lack of information
on the secretoneurin receptor and the intracellular signaling
pathways induced by secretoneurin are considered the main
obstacle preventing a more detailed understanding of SgII in
health and disease [3]. However, based on our work and the work
of other groups [13,27,28], Stat3 and Erk1/2 signaling seem to be
of paramount importance for the protection by secretoneurin
during I/R injury and apoptosis.
Circulating SgII Levels in Patients with HF
In this first report on SgII in HF, we find circulating SgII levels
to be increased in the early post-infarction phase of mice with HF
and in patients with chronic, stable HF. The modest correlation
between SgII and BNP levels suggests different pathophysiology
behind SgII and BNP production and release in HF. This was also
evident by the lack of correlation between LV SgII and BNP
mRNA levels in our HF mice. Accordingly, SgII levels seem to
represent specific pathophysiology in HF not covered by BNP.
Figure 6. The secretogranin II fragment secretoneurin has protective effects during myocardial ischemia and cardiomyocyte stress.
A, Secretoneurin (SN) perfusion reduces infarct size by 30% (upper left) as demonstrated in representative TTC stained images (upper right) after
global ischemia in the isolated perfused rat heart. B, Secretoneurin perfusion also improves myocardial function as assessed by LV end-diastolic
pressure (LVEDP) after I/R injury. C, Cardiomyocyte apoptosis in vitro after H2O2 exposure was attenuated by secretoneurin stimulation. Cells were
extracted from 5 different cell isolations (n=5 for all groups). D, Short-term stimulation of cardiomyocytes with 10 mg/mL secretoneurin activated
protective intracellular pathways as reflected by increased Stat3 and Erk1/2 phosphorylation (n=5 for all groups). **p,0.001, *p,0.01, # p,0.05.
doi:10.1371/journal.pone.0037401.g006
Table 2. Descriptive statistics of heart failure patients and control subjects.
Control subjects
(n=20)
HF patients
(n=58) p
Male sex (n, %) 16 (80%) 47 (81%) 0.92
Age, years (mean 6 SEM) 60.661.1 62.861.6 0.43
NYHA class (n, %)
II 47 (81%)
III 11 (19%)
Etiology for HF (n, %)
Ischemic 35 (60%)
Dilated cardiomyopathy 21 (36%)
Other 2 (4%)
Duration of HF, months (median, Q1–3) 18 (12–48)
LVEF, % (mean 6 SEM) 3361
Medication (n, %)
b-blocker 57 (98%)
ACEI 41 (71%)
ARB 17 (29%)
ACEI or ARB 58 (100%)
Aldosterone antagonist 11 (19%)
Diuretic 43 (74%)
Statin 38 (65%)
Warfarin 29 (50%)
ASA 34 (59%)
Clopidogrel 7 (12%)
Digitalis 14 (24%)
Amiodarone 6 (10%)
Nitrate 6 (10%)
PPI 8 (14%)
CRT 10 (17%)
ICD 11 (19%)
CgA levels, nmol/L 4.5 (4.0–5.3) 5.0 (3.5–8.2) 0.33
CgB levels, nmol/L 1.47 (1.39–1.58) 1.63 (1.44–1.80) 0.02
BNP levels, pg/mL 26 (13–37) 197 (89–338) ,0.001
NYHA class indicates New York Heart Association functional class; Q1–3, quartile 1–3; LVEF, left ventricular ejection fraction; ACEI, angiotensin converting enzyme
inhibitor; ARB, angiotensin II receptor blocker; ASA, acetyl salicylic acid; PPI, proton pump inhibitor; CRT, cardiac resynchronization therapy; ICD, implantable
cardioverter-defibrillator; CgA, chromogranin A; CgB, chromogranin B; and BNP, B-type natriuretic peptide. Biomarker levels are presented as median (quartile 1–3).
doi:10.1371/journal.pone.0037401.t002
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in relation to the increasing recognition of the other granin
proteins CgA and CgB as candidate HF biomarkers [2,34]. CgA
has been demonstrated to provide incremental prognostic
information to established indices of risk, including BNP, in
several cohorts of patients with cardiac disease [4,7–9], while CgB
has been proposed as a marker associated with cardiomyocyte
calcium handling [35]. Accordingly, that we find circulating SgII
levels to better discriminate HF patients from control subjects
compared to CgA and CgB levels indicates a potential also for SgII
as a new HF biomarker. Whether high SgII levels in patients with
stable HF are primarily reflective of I/R injury and cardiomyocyte
apoptosis is not clear, but given the multifaceted properties of
secretoneurin and SgII [3], additional pathophysiology may be
associated with SgII as a biomarker and this should be explored in
future studies.
Conclusion
We have observed increased myocardial SgII production and
processing to shorter fragments in animals with myocardial
infarction and HF. This could be beneficial as the SgII fragment
secretoneurin protects from I/R injury and cardiomyocyte
apoptosis. As SgII production was not enhanced in other tissues
investigated, LV SgII production could be a significant contributor
to the elevated circulating levels of SgII in patients with HF.
Methods
Animal experiments were performed according to recommen-
dations from the European Council for Laboratory Animal
Science and approved by the Norwegian Council for Animal
Research (#HR0506). The study protocol of the clinical study was
approved by the South-Eastern Regional Ethics Committee
Norway (#1.2006.2653) before the initiation of the study, and
all participants gave their written informed consent prior to study
commencement.
Mouse Model of HF
Mice were anesthetized with 0.2 mg propofol in the tail vein,
trachetomized, connected to an animal ventilator, and ventilated
with a mixture of 98% oxygen and 2% isoflurane during surgery.
A permanent ligation of the left main coronary artery was
performed in mice and the animals were evaluated by echocar-
diography for development of HF [36]. The echocardiographic
study was performed in 2-D view and per standard guidelines [37]
by Vivid 7 (GE Vingmed, Horten, Norway). Images were stored in
Echopac (GE Vingmed) and later processed and evaluated by an
experienced researcher in small animal echocardiography (IS) with
no knowledge of circulating SgII levels. Sham-operated (sham)
animals underwent the same procedure without coronary artery
ligation. All efforts were made to minimize suffering. Animals were
sacrificed at one week post-surgery, when hearts and other organs
were dissected, prepared, and stored as previously described [6].
RT-qPCR, Radioimmunoassays, Immunhistochemistry,
and Immunoblotting
mRNA levels were measured with TaqMan Gene Expression
assays from Applied Biosystems (Foster City, CA, USA): (i) mouse
myocardium: SgII (Mm00843883_s1), CgA (Mm00514341_m1),
CgB (Mm00483287_m1), BNP (Mm00435304_g1), ribosomal
protein L4 (RPL4) (Mm00834993_g1); and (ii) neonatal rat
cardiomyocytes: SgII (Rn01400686_g1) and RPL4
(Rn00821091_g1). SgII protein levels in tissue and plasma were
measured by a RIA binding to the secretoneurin region of SgII
(SgII154–165) [38]. The detection limit of the SgII RIA in plasma is
0.05 nmol/L and the assay has a coefficient of variation (CV) of
Figure 7. Circulating SgII levels are elevated in patients with chronic, stable HF. SgII levels were significantly increased in HF patients
(n=58) compared to healthy age- and gender-matched control subjects (n=20): Median 0.16 (Q1–3 0.14–0.18) vs. 0.12 (0.10–0.14) nmol/L, p,0.001.
HF patients are presented according to NYHA functional class. The horizontal line within the box represents the median level, the boundaries of the
box the 25
th and 75
th percentile levels, and the whiskers the 10
th–90
th percentile. **p,0.001.
doi:10.1371/journal.pone.0037401.g007
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(3.80 nmol/L). We used a commercial RIA for CgA analysis
(EuroDiagnostica AB, Malmo ¨, Sweden) with a detection limit of
0.8 nmol/L and a CV of 13% in the lower range (3.1 nmol/L)
and 9% in the upper range (17.0 nmol/L), while an in-house RIA
was used for CgB analysis with detection limit $0.80 nmol/L and
a CV of 17% in the lower range (1.40 nmol/L) and 8% in the
upper range (6.40 nmol/L) [39]. For immunoblotting we used an
N-terminal SgII antibody (ab20246, Abcam, Cambridge, UK) as
SgII processing has been reported to start from the C-terminal end
[18]. We quantitated four bands of SgII (81, 66, 55, and 32-
30 kDa) according to previous data on SgII processing in non-
cardiac tissue [18]. Additional antibodies for immunoblotting and
immunhistochemistry are reported in Supporting Information S2.
Regulation of SgII mRNA Production in Neonatal Rat
Cardiomyocytes
After 24 h starvation of the cells, neonatal rat cardiomyocytes
were stimulated as previously reported [6] for 24 h with the
following agents; forskolin (FSK) [10 mM], norepinephrine (NE)
[100 mM], endothelin-1 (ET-1) [250 ng/mL], angiotensin II
(AngII) [1 mM] (all Sigma-Aldrich, St. Louis, MO, USA), tumor
necrosis factor-a (TNF-a) [10 ng/mL] (BioSource International,
Camarillo, CA, USA), and transforming growth factor-b (TGF-b)
[10 ng/mL] (R&D Systems, Minneapolis, MN, USA).
Langendorff Perfusion
All rats were anesthetized with 5% sodium pentobarbital (60–
80 mg/kg intraperitoneally (i.p)) and heparinised (500 IU i.p).
After anesthesia, rat hearts were rapidly excised and placed in ice-
cold Krebs-Henseleit Buffer (KHB) (mmol/L: NaCl 118.5;
NaHCO3 25; KCl 4.7; KH2PO4 1.2; MgSO4/7H2O 1.2;
glucose/1H2O 11.1; CaCl2 1.8) for further dissection. After aortic
cannulation, the hearts were mounted on a Langendorff system
(AD Instruments Pty Ltd, Castle Hill, NSW 2154, Australia) and
retrogradely perfused with warm (37uC), oxygenated (95% O2,5 %
CO2) KHB at constant pressure of 70 mmHg. After 40 min of
stabilization, hearts were subjected to 30 min of global ischemia,
and then reperfused for 120 min (Supporting Information Figure
S1). In the experimental group (secretoneurin group), 0.66 mg/mL
secretoneurin (NeoMPS, Strasbourg, France) was added to the
perfusate 20 min prior to ischemia, and was also used throughout
the reperfusion period. The effect of local production was taken in
account when deciding the concentration of secretoneurin for the
Langendorff model as previous reports on other secreted proteins
have demonstrated that local tissue concentrations and levels in
supernatants of stimulated cells may be .100 fold higher than
levels observed in the peripheral circulation [40,41]. A recircula-
tion system was inserted from 20 min prior to induction of
ischemia in both groups (Supporting Information Figure S1), and
used throughout the reperfusion period. Infarct size was calculated
with Adobe Photoshop (Adobe Systems, San Jose, CA, USA) as
percentage of the total area by an investigator blinded to
treatment.
Effect of Secretoneurin on Phosphoproteins
To assess the short-term effect of secretoneurin stimulation on
phosphoproteins, the cardiomyocytes were stimulated for 10 or
30 min with 10 mg/mL secretoneurin (NeoMPS) or vehicle. Cells
were harvested in lysis buffer (Tris pH 7.6, 5 M NaCl, 0.5 M
EDTA, 0.1 M EGTA, 1 M B-gly [Sigma-Aldrich St. Louis, MO,
USA] and NP-40), and the protein levels measured by immuno-
blotting (details reported in Supporting Information S2).
Cell Death Enzyme-linked Immunosorbent Assay
Neonatal rat cardiomyocytes were stimulated with 10 mg/mL
secretoneurin (NeoMPS) or vehicle for 24 h, followed by 24 h
exposure to hydrogen peroxide (H2O2, 100 mmol) in the presence
of secretoneurin or vehicle. Cells were then harvested in lysis
buffer and apoptosis assessed using the Cell Death Enzyme-linked
Immunosorbent Assay (Cell Death Detection ELISA
PLUS, Roche,
Basel, Switzerland) according to manufacturer procedure.
Patients with Stable HF and Control Subjects
Fifty-eight patients with echocardiographically documented
impaired systolic function [LV ejection fraction (LVEF) #50%],
and no hospitalization for HF during the last three months prior to
study commencement, were compared to 20 control subjects with
no history or current symptoms of chronic disease. The control
subjects had a normal physical examination, did not use
medication regularly, and were hospital employees or recruited
from outside of the hospital.
Statistical Analysis
Continuous data are presented as mean (6 SEM) or median
(quartile [Q] 1–3) and categorical values as counts (percentage).
Continuous variables were compared by Student’s t-test except
circulating biomarker values in patients that were compared by the
Mann-Whitney U-test due to a severe right-skewed distribution
(p,0.001). Serial data were compared by Two-Way ANOVA,
and categorical data by the chi-square test or Fisher’s exact test as
appropriate. Correlations were calculated by Spearman rank
correlation. P-values ,0.05 were considered significant for all
analyses. Statistical analyses were performed with SPSS for
Windows version 16.0 (SPSS, Chicago, IL) except receiver
operating analysis which was performed with MedCalc for
Windows, version 9.5.1.0 (MedCalc Software, Mariakerke,
Belgium) by the method of Hanley and McNeil [42].
Details regarding methods can be found in the Supporting
Information S2.
Supporting Information
Figure S1 Hearts from male adult rats were rapidly excised and
mounted on a Langendorff system. After 40 min of stabilization,
hearts were subjected to 30 min of global ischemia, and then
reperfused for 120 min. In the experimental group (secretoneurin
group), 0.66 mg/mL secretoneurin (SN) was added to the perfusate
20 min prior to ischemia, and also used throughout the
reperfusion period.
(TIF)
Table S1 Correlations between mRNA levels of granins and
BNP in the left ventricle of heart failure and sham-operated mice.
(DOC)
Table S2 Correlations between circulating levels of granin
proteins and BNP in patients with heart failure and healthy
control subjects.
(DOC)
Supporting Information S1 Enhanced albumin levels in
pulmonary tissue of HF animals were identified by mass
spectrometry peptide mass fingerprinting. Coomassie stained
protein bands were cut out from SDS-polyacrylamide gels and
identified by mass spectrometry peptide mass fingerprinting. A,
Representative Commassie stained gel from pulmonary tissue with
arrow indicating extracted band for mass spectrometry peptide
mass fingerprinting. B, Results for the mass spectrometry peptide
mass fingerprinting identifying albumin for all 8 samples after
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PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e37401searching the NCBI database. Significant hits for sample 1.1 are
given below and they all represent slightly different variants of
albumin. The same proteins were reported for the other 7 samples.
All the main signals in the spectra are assigned to albumin.
(DOC)
Supporting Information S2 Supplemental methods.
(DOC)
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